Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPNEUCHIM: capsaicin patch versus duloxetine for painful chemotherapy-induced peripheral neuropathy
2023-504618-31-00Phase 3Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Capsaicin patch arm with Duloxetine arm (2 arms). Primary endpoint: 30% pain improvement at week 6. Planned start Aug 2023; status: authorised.
02
Drugs
capsaicinduloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2023-504618-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504618-31-00.